Literature DB >> 31822558

The deubiquitinase USP7 stabilizes Maf proteins to promote myeloma cell survival.

Yuanming He1,2, Siyu Wang1, Jiefei Tong3, Shuoyi Jiang1,2, Ye Yang4, Zubin Zhang1, Yujia Xu1, Yuanying Zeng5, Biyin Cao6, Michael F Moran3, Xinliang Mao7,2,8.   

Abstract

The Maf proteins, including c-Maf, MafA, and MafB, are critical transcription factors in myelomagenesis. Previous studies demonstrated that Maf proteins are processed by the ubiquitin-proteasome pathway, but the mechanisms remain elusive. This study applied MS to identify MafB ubiquitination-associated proteins and found that the ubiquitin-specific protease USP7 was present in the MafB interactome. Moreover, USP7 also interacted with c-Maf and MafA and blocked their polyubiquitination and degradation. Consistently, knockdown of USP7 resulted in Maf protein degradation along with increased polyubiquitination levels. The action of USP7 thus promoted Maf transcriptional activity as evidenced by luciferase assays and by the up-regulation of the expression of Maf-modulated genes. Furthermore, USP7 was up-regulated in myeloma cells, and it was negatively associated with the survival of myeloma patients. USP7 promoted myeloma cell survival, and when it was inhibited by its specific inhibitor P5091, myeloma cell lines underwent apoptosis. These results therefore demonstrated that USP7 is a deubiquitinase of Maf proteins and promotes MM cell survival in association with Maf stability. Given the significance of USP7 and Maf proteins in myeloma genesis, targeting the USP7/Maf axle is a potential strategy to the precision therapy of MM.
© 2020 He et al.

Entities:  

Keywords:  anticancer drug; cancer; deubiquitylation (deubiquitination); multiple myeloma; transcription factor

Mesh:

Substances:

Year:  2019        PMID: 31822558      PMCID: PMC7029123          DOI: 10.1074/jbc.RA119.010724

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

Review 1.  Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.

Authors:  Francisca E Reyes-Turcu; Karen H Ventii; Keith D Wilkinson
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

2.  USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168.

Authors:  Qianzheng Zhu; Nidhi Sharma; Jinshan He; Gulzar Wani; Altaf A Wani
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Structural Basis for the Inhibitory Effects of Ubistatins in the Ubiquitin-Proteasome Pathway.

Authors:  Mark A Nakasone; Timothy A Lewis; Olivier Walker; Anita Thakur; Wissam Mansour; Carlos A Castañeda; Jennifer L Goeckeler-Fried; Frank Parlati; Tsui-Fen Chou; Ortal Hayat; Daoning Zhang; Christina M Camara; Steven M Bonn; Urszula K Nowicka; Susan Krueger; Michael H Glickman; Jeffrey L Brodsky; Raymond J Deshaies; David Fushman
Journal:  Structure       Date:  2017-11-16       Impact factor: 5.006

4.  Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy.

Authors:  J Drach; J Ackermann; E Fritz; E Krömer; R Schuster; H Gisslinger; M DeSantis; N Zojer; M Fiegl; S Roka; J Schuster; R Heinz; H Ludwig; H Huber
Journal:  Blood       Date:  1998-08-01       Impact factor: 22.113

5.  Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.

Authors:  Qian Wang; Shuai Ma; Nan Song; Xin Li; Ling Liu; Shangda Yang; Xiang Ding; Lin Shan; Xing Zhou; Dongxue Su; Yue Wang; Qi Zhang; Xinhua Liu; Na Yu; Kai Zhang; Yongfeng Shang; Zhi Yao; Lei Shi
Journal:  J Clin Invest       Date:  2016-05-16       Impact factor: 14.808

6.  Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma.

Authors:  Elaine M Hurt; Adrian Wiestner; Andreas Rosenwald; A L Shaffer; Elias Campo; Tom Grogan; P Leif Bergsagel; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2004-02       Impact factor: 31.743

7.  Identification of primary MAFB target genes in multiple myeloma.

Authors:  Esther van Stralen; Marc van de Wetering; Luca Agnelli; Antonino Neri; Hans C Clevers; Bert J E G Bast
Journal:  Exp Hematol       Date:  2008-11-13       Impact factor: 3.084

8.  The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice.

Authors:  Zubin Zhang; Jiefei Tong; Xiaowen Tang; Jiaxiang Juan; Biyin Cao; Rose Hurren; Guodong Chen; Paul Taylor; Xin Xu; Chang-Xin Shi; Juan Du; Jian Hou; Guanghui Wang; Depei Wu; A Keith Stewart; Aaron D Schimmer; Michael F Moran; Xinliang Mao
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

9.  Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.

Authors:  Xiang Ling; Diane Calinski; Asher A Chanan-Khan; Muxiang Zhou; Fengzhi Li
Journal:  J Exp Clin Cancer Res       Date:  2010-01-22

10.  BRE/BRCC45 regulates CDC25A stability by recruiting USP7 in response to DNA damage.

Authors:  Kajal Biswas; Subha Philip; Aditya Yadav; Betty K Martin; Sandra Burkett; Vaibhav Singh; Anav Babbar; Susan Lynn North; Suhwan Chang; Shyam K Sharan
Journal:  Nat Commun       Date:  2018-02-07       Impact factor: 14.919

View more
  12 in total

Review 1.  Deubiquitinases: Pro-oncogenic Activity and Therapeutic Targeting in Blood Malignancies.

Authors:  Blanca T Gutierrez-Diaz; Wei Gu; Panagiotis Ntziachristos
Journal:  Trends Immunol       Date:  2020-03-02       Impact factor: 16.687

Review 2.  Ubiquitin-proteasome system (UPS) as a target for anticancer treatment.

Authors:  Jinyoung Park; Jinhong Cho; Eun Joo Song
Journal:  Arch Pharm Res       Date:  2020-11-09       Impact factor: 4.946

3.  Suppression of USP7 induces BCR-ABL degradation and chronic myelogenous leukemia cell apoptosis.

Authors:  Shuoyi Jiang; Xiaoge Wang; Yuanming He; Hongbiao Huang; Biyin Cao; Zubin Zhang; Jinbao Liu; Qi Wang; Zhenqian Huang; Xinliang Mao
Journal:  Cell Death Dis       Date:  2021-05-07       Impact factor: 8.469

Review 4.  Deubiquitinases: Modulators of Different Types of Regulated Cell Death.

Authors:  Choong-Sil Lee; Seungyeon Kim; Gyuho Hwang; Jaewhan Song
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

Review 5.  The USP7 protein interaction network and its roles in tumorigenesis.

Authors:  Ahood Al-Eidan; Yihua Wang; Paul Skipp; Rob M Ewing
Journal:  Genes Dis       Date:  2020-10-22

6.  Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids.

Authors:  Qingguo Li; Huizhen Sun; Dakui Luo; Lu Gan; Shaobo Mo; Weixing Dai; Lei Liang; Yufei Yang; Midie Xu; Jing Li; Peiyong Zheng; Xinxiang Li; Yan Li; Ziliang Wang
Journal:  J Exp Clin Cancer Res       Date:  2021-11-05

Review 7.  The emerging role of deubiquitylating enzymes as therapeutic targets in cancer metabolism.

Authors:  Rongfu Tu; Junpeng Ma; Peng Zhang; Ye Kang; Xiaofan Xiong; Junsheng Zhu; Miao Li; Chengsheng Zhang
Journal:  Cancer Cell Int       Date:  2022-03-20       Impact factor: 5.722

Review 8.  Deubiquitinating Enzymes Orchestrate the Cancer Stem Cell-Immunosuppressive Niche Dialogue: New Perspectives and Therapeutic Potential.

Authors:  Jun-Nan Guo; Bai-Rong Xia; Shen-Hui Deng; Chang Yang; Ya-Nan Pi; Bin-Bin Cui; Wei-Lin Jin
Journal:  Front Cell Dev Biol       Date:  2021-06-09

9.  Anti-bacterial and anti-viral nanchangmycin displays anti-myeloma activity by targeting Otub1 and c-Maf.

Authors:  Yujia Xu; Tong Sun; Kun Zeng; Min Xu; Jinhao Chen; Xiaofeng Xu; Zubin Zhang; Biyin Cao; Xiaowen Tang; Depei Wu; Yan Kong; Yuanying Zeng; Xinliang Mao
Journal:  Cell Death Dis       Date:  2020-09-30       Impact factor: 8.469

Review 10.  The Role of AP-1 Transcription Factors in Plasma Cell Biology and Multiple Myeloma Pathophysiology.

Authors:  Fengjuan Fan; Klaus Podar
Journal:  Cancers (Basel)       Date:  2021-05-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.